drugset / Trial / NCT06275360
Repositioning Immunotherapy in VetArans With Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2027-02-28
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | — |